Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results

Core Viewpoint - Innate Pharma will hold a conference call and webcast on March 26, 2026, to discuss its financial results for the full year ending December 31, 2025 [1]. Group 1: Conference Call Details - The conference call is scheduled for 2 p.m. CET / 9 a.m. EDT [1]. - A live webcast will be available at a specified link, and participants can also join via telephone using a registration link [2]. - A replay of the webcast will be accessible on the company website for 90 days following the event [2]. Group 2: Company Overview - Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients [3]. - The company specializes in antibody-engineering and innovative target identification to create next-generation antibody therapeutics [3]. Group 3: Product Pipeline - Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, including IPH4502, lacutamab, and monalizumab, targeting high unmet medical needs in oncology [4]. - IPH4502 is a Nectin-4 ADC for solid tumors, lacutamab is an anti-KIR3DL2 antibody for cutaneous T cell lymphomas, and monalizumab is an anti-NKG2A antibody developed in collaboration with AstraZeneca for non-small cell lung cancer [4]. Group 4: Collaborations - The company has established collaborations with leading biopharmaceutical companies such as Sanofi and AstraZeneca, as well as academic and research institutions to enhance innovation in immuno-oncology [5].